The Untapped Potential of AI: Healthcare on the Brink of Transformation
Tempus AI Wins FDA Clearance for Cardiac Imaging Platform
Drug Development Costs Could Be Cut by 50%
Tempus AI, a U.S.-based artificial intelligence healthcare company, has received premarket clearance from the U.S. Food and Drug Administration (FDA) for its cardiac imaging platform.
Unlike conventional MRI systems, which primarily display differences in image brightness, Tempus AI’s technology quantifies the characteristics of cardiac tissue. This enables the early detection of heart conditions that were difficult to identify using traditional methods. Following news of the FDA approval on the 11th, Tempus AI shares surged 13.59%, reflecting heightened investor expectations and renewed interest in the global medical AI theme.
In healthcare, the application of AI is widely expected to shorten drug development timelines by 20% to 50% and cut costs by as much as 50%. In oncology in particular, some scenarios suggest that new cancer therapies could be developed twice as fast at just one-third of the traditional cost. Larry Ellison, chairman of Oracle and recently the world’s wealthiest individual, has also hinted at the imminent realization of personalized cancer vaccines.
Two leading players in medical AI are Tempus AI (TEMPUS AI, TEM) and Recursion Pharmaceuticals (RXRX). Tempus AI is a precision medicine company that leverages AI for diagnostics and data licensing, supported by a vast database of more than 40 million clinical and genomic patient records. The company drew further market attention after being included in the investment portfolio of former U.S. House Speaker Nancy Pelosi and her husband, known for their strong track record in stock investing.
Recursion Pharmaceuticals, the second major name in the space, gained prominence in 2023 after receiving investment from Nvidia. Its share price has recently struggled following clinical trial results that fell short of expectations. Nevertheless, Recursion continues to work on multiple projects with major pharmaceutical companies such as Roche, Sanofi, and Merck, and currently has five drug candidates across various stages of development, including preclinical trials—underscoring its significant long-term potential.
In July, the 1Q U.S. Medical AI ETF (0083S0), which focuses on U.S. medical AI stocks, was listed in Korea. A comparable product is the U.S.-listed ARK Genomic Revolution ETF (ARKG), launched by Cathie Wood’s ARK Investment Management. While ARKG is not exclusively dedicated to medical AI, its strong growth-stock orientation results in substantial exposure to leading medical AI companies. When comparing holdings in Tempus AI and Recursion alone, the weight in the 1Q ETF is more than double that of ARKG.
Over the past five years, the S&P Healthcare Index has returned 34.42%, trailing the S&P 500’s 105.66% gain by 71.23 percentage points. This underperformance reflects the dominance of large technology companies in driving broader market returns. Traditionally, patience has been a core principle of biotech investing, largely due to the lengthy FDA approval process. The next step is assessing whether approved products can scale into large markets and generate sustainable profits.
Experts expect AI technology to shorten the waiting period inherent in traditional biotech investing while significantly expanding market size. Cost reductions could also improve profitability for large pharmaceutical companies, potentially reshaping long-established investment patterns in biotech and pharma stocks. The acceleration of earnings growth at Tempus AI and the confirmation of clinical approvals at Recursion Pharmaceuticals may mark the beginning of that transformation.